JP2000513351A5 - - Google Patents

Download PDF

Info

Publication number
JP2000513351A5
JP2000513351A5 JP1998502558A JP50255898A JP2000513351A5 JP 2000513351 A5 JP2000513351 A5 JP 2000513351A5 JP 1998502558 A JP1998502558 A JP 1998502558A JP 50255898 A JP50255898 A JP 50255898A JP 2000513351 A5 JP2000513351 A5 JP 2000513351A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998502558A
Other languages
English (en)
Japanese (ja)
Other versions
JP4162263B2 (ja
JP2000513351A (ja
Filing date
Publication date
Priority claimed from GBGB9613182.6A external-priority patent/GB9613182D0/en
Application filed filed Critical
Publication of JP2000513351A publication Critical patent/JP2000513351A/ja
Publication of JP2000513351A5 publication Critical patent/JP2000513351A5/ja
Application granted granted Critical
Publication of JP4162263B2 publication Critical patent/JP4162263B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50255898A 1996-06-24 1997-06-24 フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート Expired - Lifetime JP4162263B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9613182.6 1996-06-24
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (3)

Publication Number Publication Date
JP2000513351A JP2000513351A (ja) 2000-10-10
JP2000513351A5 true JP2000513351A5 (Direct) 2005-02-10
JP4162263B2 JP4162263B2 (ja) 2008-10-08

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50255798A Expired - Lifetime JP4359651B2 (ja) 1996-06-24 1997-06-24 マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少
JP50255898A Expired - Lifetime JP4162263B2 (ja) 1996-06-24 1997-06-24 フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50255798A Expired - Lifetime JP4359651B2 (ja) 1996-06-24 1997-06-24 マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少

Country Status (14)

Country Link
US (2) US6258828B1 (Direct)
EP (2) EP0910360B1 (Direct)
JP (2) JP4359651B2 (Direct)
CN (2) CN1228703A (Direct)
AT (2) ATE228361T1 (Direct)
AU (2) AU720570B2 (Direct)
BR (1) BR9709942A (Direct)
CA (2) CA2258299A1 (Direct)
DE (2) DE69716104T2 (Direct)
GB (1) GB9613182D0 (Direct)
IL (1) IL127733A0 (Direct)
NO (2) NO985916L (Direct)
NZ (2) NZ333315A (Direct)
WO (2) WO1997049390A1 (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1060174B1 (en) * 1997-12-23 2004-09-22 Amersham Health AS Nitric oxide releasing chelating agents and their therapeutic use
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR20100075503A (ko) 1999-10-01 2010-07-02 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
CA2564542C (en) 2004-04-22 2012-11-27 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
SI3311805T1 (sl) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
US8377969B2 (en) * 2007-12-14 2013-02-19 Pledpharma Ab Compounds for use in the treatment of cancer
JP5868852B2 (ja) * 2009-07-06 2016-02-24 プレッドファルマ・アーベー マンガン錯体化合物と非マンガン錯体形態の同化合物の組み合わせを用いる医薬組成物及び治療方法
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
WO2013102806A1 (en) 2012-01-05 2013-07-11 Pledpharma Ab Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
ES2899643T3 (es) 2012-10-01 2022-03-14 Mayo Found Medical Education & Res Tratamientos para el cáncer
BR112015009963A2 (pt) 2012-11-02 2017-07-11 Pledpharma Ab uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer
WO2015191969A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Treating lymphomas
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
RU2019110071A (ru) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способы лечения злокачественных новообразований, экспрессирующих pd-l1
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Similar Documents

Publication Publication Date Title
JP2001502742A5 (Direct)
JP2000502280A5 (Direct)
JP2000501771A5 (Direct)
JP2001504330A5 (Direct)
JP2000501599A5 (Direct)
JP2001504720A5 (Direct)
JP2000502472A5 (Direct)
JP2000501825A5 (Direct)
JP2000507722A5 (Direct)
JP2001504644A5 (Direct)
JP2000502425A5 (Direct)
JP2000502485A5 (Direct)
JP2000502568A5 (Direct)
JP2000501774A5 (Direct)
JP2000502570A5 (Direct)
JP2001500441A5 (Direct)
JP2000501876A5 (Direct)
JP2000513351A5 (Direct)
JP2000501744A5 (Direct)
JP2000514044A5 (Direct)
JP2000502316A5 (Direct)
JP2001509329A5 (Direct)
JP2000502714A5 (Direct)
JP2002514082A5 (Direct)
JP2000502479A5 (Direct)